Cisplatin and ultra-violet-C synergistically down-regulate receptor tyrosine kinases in human colorectal cancer cells by Junji Kawaguchi et al.
Kawaguchi et al. Molecular Cancer 2012, 11:45
http://www.molecular-cancer.com/content/11/1/45RESEARCH Open AccessCisplatin and ultra-violet-C synergistically
down-regulate receptor tyrosine kinases in
human colorectal cancer cells
Junji Kawaguchi1, Seiji Adachi1,2,3*, Ichiro Yasuda1, Takahiro Yamauchi1, Masanori Nakashima1, Tomohiko Ohno1,
Masahito Shimizu1, Takashi Yoshioka2, Masahiko Itani2, Osamu Kozawa2 and Hisataka Moriwaki1Abstract
Background: Platinum-containing anti-cancer drugs such as cisplatin are widely used for patients with various
types of cancers, however, resistance to cisplatin is observed in some cases. Whereas we have recently reported
that high dose UV-C (200 J/m²) induces colorectal cancer cell proliferation by desensitization of EGFR, which leads
oncogenic signaling in these cells, in this study we investigated the combination effect of low dose cisplatin
(10 μM) and low dose UV-C (10 J/m²) on cell growth and apoptosis in several human colorectal cancer cells, SW480,
DLD-1, HT29 and HCT116.
Results: The combination inhibited cell cycle and colony formation, while either cisplatin or UV-C alone had little
effect. The combination also induced apoptosis in these cells. In addition, the combination caused the
downregulation of EGFR and HER2. Moreover, UV-C alone caused the transient internalization of the EGFR, but with
time EGFR recycled back to the cell surface, while cisplatin did not affect its localization. Surprisingly, the
combination caused persistent internalization of the EGFR, which results in the lasting downregulation of the EGFR.
Conclusions: The combination of low dose cisplatin and low dose UV-C synergistically exerted anti-cancer effect by
down-regulating RTK, such as EGFR and HER2. These findings may provide a novel strategy for the treatment of
patients with colorectal cancer.
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Among the receptor tyrosine kinases (RTKs), the ErbB
family, such as epidermal growth factor receptor (EGFR;
ErbB1) or human epidermal growth factor receptor-2
(HER2; ErbB2) plays a pivotal role in regulating a num-
ber of cellular processes including cell proliferation, sur-
vival and migration [1], and dysregulation of EGFR
activity leads to tumorgenesis [2]. Mechanisms leading
to oncogenic signaling behind EGFR are thought as
follows: 1) increased EGFR levels, 2) autocrine and/or
paracrine growth factor loops, 3) heterodimerization
with other EGFR family members and cross-talk with* Correspondence: seijiadachi0123@gmail.com
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distribution, and reproduction in any mediumheterologous receptor systems, 4) defective receptor
downregulation, and 5) activating mutations [3].
We have previously reported that the blockade of EGF
stimulation significantly suppressed colorectal cancer
cell growth, suggesting that the EGFR pathway plays an
important role in proliferation of these cells [4]. Thus,
EGFR downregulation is a critical target for therapy
against colorectal cancer that is highly dependent on
EGFR. As for HER2, their expression has been first
reported to be amplified in breast cancer [5]. Since clin-
ical and experimental evidences show a role for over-
expression of the HER2 protein in the progression of
human breast, ovarian, non-small cell lung [6] and colo-
rectal cancer [7], HER2 may be a candidate target for
receptor-targeted therapeutics.
Cis-diamminedichloroplatinum (CDDP) or cisplatin is
one of the most effective DNA-damaging anti-tumortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cancers [8-10]. However, resistance to cisplatin arises in
some cases and many compounds combined with
platinum-based drugs are now ongoing clinical trials
[11]. Increasing evidences show that cisplatin directly
influences EGFR signaling. Cisplatin reportedly induces
EGFR internalization [12], phosphorylation at Thr1045
mediated via a ubiquitin ligase, c-Cbl [13] and phosphor-
ylation at Thr669, at a site which is phosphorylated by
p38 MAPK [14], while activation of stress-activated pro-
tein kinase/c-Jun-N-terminal kinase or p38 MAPK by
cisplatin has been reported to promote apoptotic cell
death [15]. In addition, in many studies researchers have
used cisplatin at relatively higher doses (30 μM or more),
which is impractical in vivo.
Ultra-violet (UV) radiation is divided into three bands:
UV-A (320–400 nm), UV-B (280–320 nm) and UV-C
(200–280 nm). Most of the UV-C and approximately
90% of UV-B are absorbed while passing through the at-
mospheric layers. UV-A and UV-B are recognized harm-
ful for humans, while UV-C is used for studying DNA
damage and cellular DNA repair process [16]. So far, the
possibility of application rather for treatment of human
cancer has been demonstrated [17,18]. In a series of
papers, Petersen et al have investigated the photophysi-
cal consequences of illuminating the aromatic residues
of proteins with UV-C [19-25]. In particular, they
demonstrated that 280 nm UV illumination of aromatic
residues in proteins causes the disruption of nearby di-
sulphide bridges, where EGFR are excessively populated,
leading to the suppression of the proliferative potential
in human cancer cell lines [17].
Whereas we recently reported the availability of UV-C
alone (30 J/m² and more) in human colorectal cancer
cells, in which we showed that UV-C can evade these
cells from oncogenic stimulation of EGF by decreasing
the EGFR protein level [26], we herein investigated the
combination use of low dose cisplatin and low dose
UV-C on cell growth in human colorectal cancer cells
(SW480, HT29, DLD-1 and HCT116) and found that
the combination has synergistic effect on cell growth in-
hibition by down-regulating receptor tyrosine kinases,
such as EGFR and HER2.
Results
Effects of cisplatin and/or UV-C on cell proliferation in
human colorectal cancer cells
Bromodeoxyuridine (BrdU) is a synthetic thymidine
analog that gets incorporated into DNA during cell div-
ision. Therefore, the measurement of BrdU incorpor-
ation reflects the ability of cell growth. We first
investigated the effects of cisplatin and/or UV-C on cell
proliferation using BrdU. Whereas either 10 μM of cis-
platin or 10 J/m² of UV-C hardly affected BrdUincorporation in SW480 and DLD-1 cells (Figure 1A,
lanes 2 and 3, respectively), the combination caused a
marked inhibition in BrdU incorporation (Figure 1A,
lane 4, respectively). While it has previously been
reported that cisplatin induces cell cycle arrest at the
G2-phase [27], cell cycle analysis using flow cytometry
revealed that the combination of cisplatin and UV-C
increased the population at G2/M phases (28.2 ± 1.35%),
compared with cisplatin (21.9 ± 0.68%; p = 0.0014) or
UV-C (15.2 ± 0.76%; p = 0.0004) (Figure 1B). Moreover,
we examined the protein level of phospho-Rb and cyc-
lin D1, both of which direct cells toward proliferation
by controlling progression through the restriction point
of cell cycle (Figure 2A) [28]. In SW480 cells, cisplatin
by itself had little effect on phosphorylation level of Rb.
However, when the cells were first exposed to UV-C
and then incubated in the presence of cisplatin, the
protein level of phospho-Rb was decreased in a time-
dependent manner after 12 h (Figure 2). Since we have
recently reported that 10 J/m² of UV-C did not cause
the decrease in the protein level of Rb [26], these
results suggest that the combination of cisplatin and
UV-C exerts synergistic effect on the suppression of cell
cycle. We also verified the combination effect in DLD-1,
HT29 and HCT116, other human colorectal cancer cell
lines (Figure 2).
Effects of cisplatin and/or UV-C on colony formation in
human colorectal cancer cells
We next performed colony formation assay, which is a
microbiology technique for studying the effectiveness of
specific agents on the survival and proliferation of cells
(Figure 2B) [29]. The combination synergistically sup-
pressed colony formation of SW480 cells, although cis-
platin or UV-C alone did to a lesser extent. Similarly,
the combination synergistically decreased the number of
colony formation in DLD-1 and HCT116 cells, whereas
UV-C alone slightly affected them in these cells. As for
HT29 cells, while cisplatin or UV-C alone has no effect,
the combination synergistically suppressed colony for-
mation. As a whole, these results suggest that the com-
bination has cytocidal effects on several colorectal
cancer cells.
Effects of cisplatin and/or UV-C on the apoptosis in
human colorectal cancer cells
We next investigated the combination effect of cisplatin
and UV-C on apoptosis by observing PARP cleavage,
since PARP is a family of proteins involved in a number
of cellular processes involving mainly DNA repair and
programmed cell death, indicating cell apoptosis [30].
While cisplatin or UV-C alone had little effect on
PARP, the combination caused PARP cleavage in
SW480, DLD-1, HT29 and HCT116 cells (Figure 3A).
Figure 1 (A) Effects of cisplatin and/or UV-C on cell proliferation in human colorectal cancer cells. SW480 and DLD-1 cells were either
exposed to 10 J/m² UV-C (lanes 3), treated with 10 μM cisplatin (lanes 2), or received both (lanes 4). Twenty four h later, the measurement of
BrdU incorporation was performed using cell proliferation ELISA (BrdU). Results are expressed as percentage of incorporation with 100%
representing that by untreated control cells (lanes 1). (B) SW480 cells were treated with 10 μM cisplatin (group 2), 10 J/m² UV-C (group 3) or
combination of 10 μM cisplatin and 10 J/m² UV-C (group 4). The cells were then stained with propidium iodide (PI) to analyze progression of cell
cycle. The distribution of cells in the apoptosis and each phase of cell cycle were calculated in each group. Bars designate SD of triplicate assay.
The asterisks (*) indicate significant decrease (p < 0.05) as compared to the corresponding control, respectively.
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detect such DNA fragments, we next examined the ef-
fect of combination of cisplatin and UV-C on DNA
fragmentation utilizing this dye and found that the
combination increased the number of Hoechst 33258-
positive apoptotic cells in SW480 and HT29 cells
(Figure 3B), which are consistent with our results
shown in Figure 3A.
Effects of cisplatin and/or UV-C on the protein level of
EGFR and HER2 in human colorectal cancer cells
As described in Introduction, EGFR downregulation is
the most prominent regulatory system in signal attenu-
ation and involves the internalization and subsequent
degradation of the activated receptor in the lysosomes.
As well, HER2 is frequently overexpressed in colorectal
cancer when compared with normal colonic mucosa,
and the extent of overexpression seems to correlate
with increasing disease stage and poorer patient sur-
vival [31]. Therefore, therapies that target the EGFR
and/or HER2 may be effective in the chemoprevention
and/or therapy of colorectal cancer [32]. Whereas we
recently reported that EGFR signaling plays a criticalrole in proliferation of colorectal cancer cells [26], we
next focused on the expression level of EGFR as well
as HER2 in several colorectal cancer cells including
SW480, DLD-1, HT29 and HCT116, since we
observed that the combination use of cisplatin and
UV-C synergistically exerts suppressive effect on cell
proliferation and apoptosis (Figures 1 and 3). As
depicted in Figure 4, 10 μM cisplatin alone did not
affect these levels even after a longer treatment in
SW480 (Figure 4, lanes 1–4). As well, while UV-C at a
dose over 30 J/m² caused a marked decrease in the
EGFR protein level [26], in this study we observed that
10 J/m² of UV-C did not affect (Additional file 1).
Interestingly, the combination use of 10 μM cisplatin
and 10 J/m² UV-C clearly induced the decrease in the
protein levels of EGFR as well as HER2 in SW480
cells, which were appeared at 12 h after treatment
with cisplatin and UV-C (Figure 4, lanes 5–8). Similar
results were observed in other colorectal cancer cells,
DLD-1, HT29 and HCT116. Together, the combination
effect of cisplatin and UV-C on the suppression of cell
growth seems to be due to the down-regulation of
EGFR and/or HER2.
Figure 2 (A) Effects of cisplatin and/or UV-C on cell proliferation markers, phospho-Rb and cyclin D1 in human colorectal cancer cells.
SW480, DLD-1, HT29 and HCT116 cells were first exposed to 10 J/m² of UV-C or not, and then treated with 10 μM of cisplatin for the indicated
periods. Protein extracts were harvested and examine by Western blotting using anti-phospho-Rb and anti-cyclin D1 antibodies. (B) Effects of
cisplatin and/or UV-C on colony formation in SW480, DLD-1, HT29 and HCT116 human colorectal cancer cells. The attached human colorectal
cancer cells were first exposed to the indicated doses UV-C (0 or 10 J/m²), just after the aspiration of the growth medium. The cells were then
incubated in normal growth media with/without 10 μM cisplatin for 24 h. After trypsinization, the counted cells (3 x 103) were re-seeded into
new culture dishes and incubated for 7 days. The cells were then fixed with clonogenic reagent (see Materials and methods) and the average
number of colony from 5 randomly chosen fields (x 20) were counted, respectively. Bars designate SD of triplicate assay. The asterisks (* and **)
indicate significant decrease (p < 0.05) as compared to the control and UV-C alone, respectively.
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EGFR in SW480 cells
It has previously been reported that UV irradiation
(100 J/m²) induces rapid and persistent internalization of
EGFR [33]. As well, we have recently reported that UV-
C at a dose over 30 J/m² caused the internalization and
subsequent down-regulation of the EGFR in SW480 cells
[26]. In order to elucidate the mechanism underlying
combination effect of cisplatin and UV-C, we next exam-
ined whether cisplatin (10 μM) and/or UV-C (10 J/m²)
induces changes in the subcellular localization ofEGFR in SW480 cells. Whereas antibody-tagged EGFR
remained on the cell surface (Figure 5A, panels 1, 6 and
11), 0.5 h incubation after the treatment of the cells with
UV-C alone (10 J/m²) resulted in the distribution of the
EGFR to cytosol beneath the plasma membrane, thus in-
dicating that UV-C indeed induced the internalization of
the EGFR (Figure 5A, panel 7). By contrast, cisplatin
(10 μM) by itself did not affect the localization of the
EGFR (Figure 5A, panels 2–5). Interestingly, when the
cells were first exposed to UV-C and then incubated in
the absence of cisplatin for 6 h and more, the antibody-
Figure 3 (A) Effects of cisplatin and/or UV-C on PARP cleavage and DNA fragmentation in human colorectal cancer cells. SW480, DLD-1,
HT29 and HCT116 cells were first exposed to the indicated doses of UV-C (0 J/m² or 10 J/m²), and then treated with/without 10 μM of cisplatin
for the indicated periods. Protein extracts were then harvested and examine by Western blotting using anti-PARP and anti-GAPDH antibodies. (B)
SW480 and HT29 cells were first exposed to the indicated doses of UV-C (0 J/m² or 10 J/m²), and then treated with/without 10 μM of cisplatin for
the indicated periods. They were then treated with Hoechst 33258 and were examined by fluorescence microscopy. The numbers of
Hoechst33258-positive cells (apoptotic nuclei) from 5 randomly chosen fields (x 40) were counted, respectively. Bars designate SD of triplicate
assay. The asterisks (*) indicate significant increase (p < 0.05) as compared to the corresponding controls, respectively.
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gesting that internalized EGFR recycled back to the cell
membrane (Figure 5A, panels 8–10). However, the EGFR
remained to be internalized when the cells were treated
with the combination of cisplatin and UV-C (Figure 5A,
panels 12–15).
To verify these results, we measured the amount of
cell surface EGFR by enzyme-linked immunosorbent
assay (ELISA). Whereas UV-C alone decreased the
amount of cell surface EGFR within 0.5 h (Figure 5B,
lane 3). However, they were gradually recovered 3 h after
treatment with UV-C (Figure 5B, lanes 3, respectively).
On the contrary, cell surface EGFR in the cells treated
with the combination of cisplatin and UV-C remained to
be decreased (Figure 5B, lanes 4, respectively). Taken to-
gether with our results obtained from fluorescence
study, we strongly suggest that the treatment with cis-
platin after UV-C exposure blocks the recycling of the
EGFR which are internalized by UV-C.Discussion
Platinum-containing anti-cancer drugs, including cis-
platin, inhibit DNA replication [34,35] and RNA
transcription [36], and induce cell cycle arrest at the
G2-phase and apoptosis [27,37]. However, cisplatin at a
higher dose concomitantly raises severe adverse effects,
such as myelo-supression, nausea, anorexia, diarrhea
and liver dysfunction. Therefore, many trials have made
effort to minimize the dose of cisplatin in cancer
patients. In the present study, we examined the combin-
ation effect of low dose cisplatin (10 μM) and low dose
UV-C (10 J/m²) on human colorectal cancer cells, while
we recently reported the potential availability of UV-C
in these cells [26].
We herein demonstrated that the combination use
synergistically inhibited the cell proliferation by BrdU
assay (Figure 1A), flow cytometry (Figure 1B), Western
blotting (Figure 2A) and colony formation assay
(Figure 2B). We also unveiled that the cisplatin and
Figure 4 Effects of cisplatin and/or UV-C on HER2 and EGFR in human colorectal cancer cells. SW480, DLD-1, HT29 and HCT116 cells were
first exposed to the indicated doses of UV-C (0 J/m² or 10 J/m²), and then treated with/without 10 μM of cisplatin for the indicated periods.
Protein extracts were then harvested and examine by Western blotting using anti-HER2, anti-EGFR and anti-GAPDH antibodies. The lower line
graphs show quantification data for the protein levels of HER2 and EGFR, after normalization to GAPDH, respectively. Bars designate SD of
triplicate assay. The asterisks (* and **) indicate significant decrease (p < 0.05) as compared to the corresponding controls, respectively.
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platin or UV-C alone had little effect (Figure 3). They
were accompanied by downregulation of RTKs, such as
EGFR and HER2 (Figure 4), both of which reportedly
play a critical role in cell proliferation in many types of
cancers including colorectal cancer [7,38].
An anti-EGFR monoclonal antibody inhibits EGFR ac-
tivation, resulting in the enhancement of the anti-cancer
effect of cisplatin [39,40]. Indeed, chemotherapy with
cetuximab or panitumumab, both of which are also anti-
EGFR monoclonal antibodies, can prolong survival
period of colorectal cancer patients by nearly twenty-
four months [41-43]. On the contrary, it has recently
been reported that EGFR inhibition can protect EGFRfrom cisplatin-mediated phosphorylation and subsequent
ubiquitination and degradation, indicating that treat-
ment with an EGFR inhibitor before cisplatin would be
antagonistic [13]. Thus, the efficacy of the combination
of cisplatin and EGFR targeting drugs remains to be elu-
cidated. In this study, low dose UV-C (10 J/m²) induced
EGFR internalization, but these receptors recycled
back to the cell surface, whereas the combination use
of cisplatin and UV-C induced persistent EGFR
internalization (Figure 5). It has previously been
reported that if cisplatin-bound EGFRs remain on the
cell surface, they catalytically inhibit cell death [33].
Therefore, we speculate that pretreatment with UV-C
helps cisplatin to induce degradation of EGFR, since
Figure 5 (See legend on next page.)
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Figure 5 (A) Effects of cisplatin and/or UV-C on the localization of EGFR in SW480 cells. SW480 cells were first labeled for 15 min at 37°C
with anti-EGFR antibodies. They were then exposed to 10 J/m² of UV-C (panels 6–10 and 11–15, respectively) or not (panels 1–5, respectively),
followed by the treatment with (panels 1–5 and 11–15, respectively) or without (panels 6–10, respectively) 10 μM of cisplatin for the indicated
periods at 37°C. After fixation and permeabilization, the cells were stained with Alexa 488W conjugated anti-mouse secondary antibody for EGFR
(green signal) and DAPI (blue signal) for 1 h, and then examined by fluorescence microscope. (B) Effects of cisplatin and/or UV-C on the amount
of cell surface EGFR in SW480 cells. SW480 cells were first labeled for 15 min at 37°C with an anti-EGFR antibody that recognizes the extracellular
domain of the EGFR. They were then exposed to 10 J/m² UV-C (lanes 3 and 4) or not (lanes 1 and 2), followed by the treatment with (lanes 2
and 4) or without 10 μM cisplatin (lanes 1 and 3) for the indicated periods at 37°C. The amount of cell surface EGFR was then measured by ELISA.
The asterisks (* and **) indicate significant decrease (p < 0.05) with respect to the control (lane 1, respectively). For additional details see Materials
and methods.
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nuclear area of the cells, where cisplatin might exert
maximum effect on the donwregulation of EGFR
(summarized in Figure 6). Nevertheless, further investi-
gation is required to elucidate why UV-C causes
EGFR internalization and why cisplatin induces EGFR
degradation.
Regarding the mechanisms underlying EGFR down-
regulation, they involve several important phosphoryl-
ation sites in EGFR, including Tyr1045, a docking site
for the ubiquitin ligase c-Cbl, and Ser1046/1047, which
are required for EGFR desensitization in EGF-treated
cells [44,45]. We recently found that (−)-epigallocate-
chin-3-gallate as well as heat shock protein 90 inhibitors
cause down-regulation of the EGFR via phosphorylation
at Ser1046/1047 through p38 MAPK in human cancer
cells [46,47]. However, we did not observe theFigure 6 Schematic representation of the combination effect of
cisplatin and UV-C in human colorectal cancer cells. After UV-C
exposure even at a low dose, cell surface EGFR is internalized. With
time the internalized EGFR by UV-C recycles back to the cell
membrane, but cisplatin blocks this recycling and induces EGFR
degradation, resulting in cell cycle arrest.phosphorylation of EGFR at these residues when the
cells were treated with low dose cisplatin and/or low
dose UV-C in colorectal cancer cells (data not shown).
Therefore, it seems that EGFR degradation by the com-
bination does not depend on Tyr1045 or Ser1046/1047.
Moreover, it has previously reported that p38 MAPK
plays an important role in 100 J/m² UV-induced EGFR
internalization [33]. However in the present study, the
combination did not influence the phosphorylation of
p38 MAPK (data not shown). These results also suggest
that the synergistic effect of cisplatin and UV-C also
does not depend on p38 MAPK activation.
Initial platinum treatment is generally responsive, but
the majority of cancer patients eventually relapse with
cisplatin-resistance [10,48]. Several mechanisms of re-
sistance to cisplatin are proposed; 1) reduced drug up-
take, 2) increased drug inactivation, 3) increased DNA
adduct repair, and 4) defective apoptotic response [10].
Importantly, a poor response of human cancers to cis-
platin is associated with amplification and over-
expression of HER2 found in some of breast and ovarian
cancer patients [10,48]. Since we showed that the com-
bination use of cisplatin and UV-C down-regulated
HER2 (Figure 4), UV-C could alter the resistance to cis-
platin in human colorectal cancer cells.
Conclusions
These results suggest that UV-C synergizes with cis-
platin in the downregulation of receptor tyrosine kinases
in human colorectal cancer cells. Our findings could
provide a new aspect for the treatment of patients with
colorectal cancer, although further investigation is
required to develop devices that supply UV-C efficiently




Antibodies against total EGFR and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies
against total HER2, cyclin D1, phospho-retinoblastoma
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purchased from Cell Signaling (Beverly, MA). Cisplatin
was purchased from Sigma Aldrich (St. Louis, MO).
ECL Western blot detection system was purchased
from GE Healthcare (Buckinghamshire, UK). Cell Pro-
liferation ELISA (BrdU) was obtained from Roche Diag-
nostics Co (Indianapolis, IN). Alexa Fluor 488W
conjugated donkey anti-mouse IgG antibodies and 4',6-
diamidino-2-phenylindole (DAPI) were purchased
from Invitrogen and Wako (Tokyo, Japan), respectively.
p2'-(4-Hydroxyphenyl)-5-(4-methyl-1-piperazinyl)-2, 5'-
bi-1 H-benzimidazole, trihydrochloride (Hoechst 33258)
solution was purchased from Dojindo (Kumamoto,
Japan). PI/RNase Staining Buffer was obtained from
Becton Dickinson (Franklin Lakes, NJ). Other materials
and chemicals were obtained from commercial sources.
Cell culture
SW480 and HT29 human colorectal cancer cells, that
were obtained from American Type Culture Collection
(Manassas, VA), were grown in Dulbecco's modified
Eagle’s medium (DMEM) (Invitrogen, San Diego, CA),
containing 10% fetal calf serum (FCS) with penicillin
(100 U/ml) and streptomycin (100 μg/ml) in a humidi-
fied 5% CO2 incubator at 37°C. DLD-1 and HCT 116
human colorectal cancer cells were from American Type
Culture Collection (Manassas, VA) and grown in Roswell
Park Memorial Institute 1640 (RPMI) (Invitrogen, San
Diego, CA) as described above.
UV-C exposure
UV-C exposure of cells was performed in UV-C 500 UV
Crosslinker (8 W 254 nm UV lamp) (GE Healthcare),
which creates CW light using 8 W 254 nm UV lamps.
Fluorescent lamps without a phosphorescent coating
emit UV with two peaks at 254 nm and 185 nm due to
the peak emission of the mercury within the bulb. UV
lamps used quartz (glass) block the 185 nm wavelength
and emit only 254 nm UV. After aspiration of the
growth medium, the cells were exposed to the indicated
dose (J/m² = 100 μJ/cm²) of UV-C in 5 sec, and then
incubated for the indicated times.
Cell proliferation assay
BrdU incorporation was measured using cell Prolifera-
tion ELISA (BrdU). The cells (7 x 103/well) were seeded
onto 96-well plates and 48 h later, the cells were exposed
to the indicated doses (0 or 10 J/m²) of UV-C, just after
the aspiration of the growth medium. The cells were
then incubated in DMEM or RPMI medium with 1%
FCS and 10 μM of cisplatin for 24 h. They were then
used for the assay according to the manufacturer’s
protocol. All assays were done at least three times.Cell cycle analysis
Cell cycle analysis was done as described previously [7].
In brief, SW480 cells were exposed to UV-C, followed
by the incubation in DMEM with/without 10 μM of cis-
platin for 96 h. The cells were then harvested and
stained with 500 μl of PI/RNase staining buffer for
15 min at room temperature. They were finally analyzed
by flow cytometry using a FACS Calibur instrument
(Becton Dickinson); data were analyzed using the CELL
Quest computer program (Becton Dickinson) as previ-
ously described. All data were obtained from at least
three independent experiments.
Colony formation assay
Human colorectal cancer cells (SW480, DLD-1, HT29
and HCT116) were exposed to UV-C and then incu-
bated in DMEM or RPMI medium and with/without
10 μM of cisplatin. Twenty four h after treatment, the
cells were trypsinized and the cells (3 x 103) were re-
seeded into fresh tissue culture dishes and incubated for
7 days. Fresh media were added at day 4. At day 7, the
media were removed and the cells were fixed with 2 ml
of clonogenic reagent (50% ethanol, 0.25% 1,9-dimethyl-
methylene blue) for 45 min. They were then washed
with PBS twice and counted the blue colonies on 5 ran-
domly chosen fields.
Western blotting
The cells were lysed in lysis buffer [20 mM Tris/HCl
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
TritonX-100, 2.5 mM sodium pyrophosphate, 50 mM
NaF, 50 mM HEPES, 1 mM Na3VO4 and 2 mM phenyl-
methylsulfonyl fluoride (PMSF)] and scraped from the
Petri dishes. Protein extracts were examined by Western
blot analysis as previously described [49,50].
Immunofluorescence microscopy studies
Immunofluorescence microscopy studies were per-
formed as described previously [46]. Live cells grown on
coverslip-bottom dishes in DMEM were first exposed to
the mouse anti-EGFR antibody that recognized the
extracellular domain of EGFR for 15 min and then
exposed to UV-C (10 J/m²) and/or cisplatin (10 μM) and
incubated in DMEM for the indicated times (0.5 h, 6 h,
12 h and 24 h) at 37°C. They were then fixed with 4%
paraformaldehyde for 10 min on ice and then exposed
to 0.1% Triton X-100 for 10 min to permeabilize the cell
membrane. They were followed by exposure to Alexa
Fluor 488W conjugated donkey anti-mouse IgG anti-
bodies (green signal) and 4',6-diamidino-2-phenylindole
(DAPI) for 1 h. The cells were then examined by fluores-
cence microscopy, BIOREVO (BZ-9000) (Keyence,
Tokyo, Japan) according to the manufacturer’s protocol.
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immunosorbent assay (ELISA)
Quantification of cell surface EGFR was performed as
described previously [26]. In brief, SW480 cells were first
exposed to the mouse anti-EGFR antibody in DMEM
containing 1% BSA, for 15 min at 37°C. The cells were
then incubated for the indicated times in DMEM with/
without 10 μM of cisplatin after exposure to UV-C, then
fixed with 4% paraformaldehyde for 10 min on ice. After
blocking with 1% BSA in PBS for 1 h, the cells were
exposed to an anti-mouse IgG, horseradish peroxidase-
linked whole antibody (GE healthcare, Piscataway, NJ)
for 1 h at room temperature, followed by washing four
times with PBS containing 1% BSA. Finally, the cells
were exposed to 50 μl of 1-stepTM Ultra TMB-ELISA
reagent (Pierce, Rockford, IL) for 5 min at room
temperature. The absorbance of each sample at 450 nm
was then measured.
Hoechst 33258 staining
Live cells grown on coverslip-bottom dishes were first
exposed to UV-C (10 J/m²) and/or cisplatin (10 μM) for
72 h and then stained with Hoechst 33258 in DMEM
without FCS for 1 h at 37°C. They were then fixed with
4% paraformaldehyde for 10 min on ice. The cells were
then examined by fluorescence microscopy, as described
above.
Densitometric analysis
The densitometric analysis was performed using scanner
and image analysis software (Image J ver. 1.45 g). The
back ground subtracted signal intensity of each protein
signal was normalized by the respective control signal.
All data were obtained from at least three independent
experiments.
Statistical analysis
The data were analyzed by ANOVA followed by Bonfer-
roni method for multiple comparisons between the indi-
cated pairs, and a p < 0.05 was considered significant.
Additional file
Additional file 1: Effect of 10 J/m² UV-C on HER2, EGFR, phospho-
Rb and cyclin D1 in human colorectal cancer cells. SW480, DLD-1,
HT29 and HCT116 cells were exposed to 10 J/m² of UV-C and then
treated for the indicated periods. Protein extracts were then harvested
and examine by Western blotting using anti-HER2, anti-EGFR, anti-
phospho-Rb, anti-cyclin D1 and anti-GAPDH antibodies.
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